Twist Bioscience purchases library designed with Distributed Bio

By The Science Advisory Board staff writers

April 12, 2021 -- Twist Bioscience plans to exercise its option to purchase all rights to a G-coupled protein receptor (GPCR) library and its Twist antibody optimization software, both of which it developed in collaboration with Distributed Bio.

The library and the software were originally built as part of a 2016 license agreement between Twist Bioscience and Distributed Bio, according to the firm. Twist has been using the GPCR library and software together with its silicon-based DNA synthesis platform for the past two years to enable synthetic DNA writing oligo pool technology.

Building on the GPCR library, Twist Biopharma, a division of Twist Bioscience, generated a wide range of precision antibody discovery libraries, which now are encompassed in what the firm calls its "library of libraries," containing antibody fragment scaffolds as well as different sources of fully human antibody sequences.

Once binding antibodies are identified from the library of libraries or other sources, Twist Biopharma utilizes the Twist antibody optimization software and its custom library capacity to further optimize leads for improved pharmacokinetic, pharmacodynamic, binding, and other properties.

Financial terms of the agreement were not disclosed.

Stanford gains access to Twist's 'library of libraries'
Twist Bioscience has granted Stanford University access to its antibody discovery and optimization services and its "library of libraries" for biologics...
Twist, Kyowa Kirin partner on antibody discovery
Twist Bioscience has inked a deal with pharmaceutical company Kyowa Kirin Pharmaceutical Research to develop novel antibodies for therapeutic use against...
Twist Bioscience inks agreements for antibody therapeutic discovery
Twist Bioscience said that its Twist Biopharma division has signed licensing deals with Serotiny and Applied StemCell aimed at discovering new antibody...
Twist to offer RNA control for U.K. strain of SARS-CoV-2
Twist Bioscience plans to offer a new synthetic RNA control that includes the new variant of SARS-CoV-2 circulating in the U.K. and South Africa.
Twist offers new gene fragments to the synthetic biology market
Twist Bioscience has launched its new clonal-ready gene fragments. The gene fragments, with and without adapters, can be used to rapidly build constructs...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter